Regenlab USA Inc. SEC filings RGNA
Regenlab USA Inc. has 7 filings in SEC EDGAR's recent list, going back to Oct 20, 2025. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| FWP | Free writing prospectus | Oct 28, 2026 | — |
| S-1/A | Amended registration statement | Oct 27, 2026 | — |
| S-1 | Registration statement | Sep 25, 2026 | — |
| DRS/A | Filing | Jun 16, 2026 | — |
| DRS/A | Filing | May 14, 2026 | — |
| DRS/A | Filing | Jan 30, 2026 | — |
| DRS | Filing | Oct 20, 2025 | — |
Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RGNA
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Jersey City, NJ
- SEC CIK
- 2084031
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.